1. Design and optimisation of potent gp120-CD4 inhibitors.
- Author
-
Tran TD, Adam FM, Calo F, Fenwick DR, Fok-Seang J, Gardner I, Hay DA, Perros M, Rawal J, Middleton DS, Parkinson T, Pickford C, Platts M, Randall A, Stephenson PT, Vuong H, and Williams DH
- Subjects
- Animals, Cells, Cultured, Drug Design, HIV Envelope Protein gp120 metabolism, HIV Fusion Inhibitors chemical synthesis, HIV Fusion Inhibitors pharmacokinetics, HIV-1 drug effects, Half-Life, Humans, Isoquinolines chemical synthesis, Isoquinolines pharmacokinetics, Nicotinic Acids chemical synthesis, Nicotinic Acids pharmacokinetics, Rats, Structure-Activity Relationship, CD4 Antigens metabolism, HIV Envelope Protein gp120 antagonists & inhibitors, HIV Fusion Inhibitors chemistry, Isoquinolines chemistry, Nicotinic Acids chemistry
- Abstract
The synthesis and structure-activity relationship of a series of novel gp120-CD4 inhibitors are described. Pharmacokinetic studies and antiviral spectrum assessment of lead compounds led to the identification of compound 36, a potent gp120-CD4 inhibitor which exhibited antiviral potency across a spectrum of 25 clade B isolates.
- Published
- 2009
- Full Text
- View/download PDF